Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic
By India Edwards HealthDay Reporter
WEDNESDAY, Jan. 22, 2025 -- Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release.
The negotiations, made possible by the Inflation Reduction Act, will cover widely used medications for conditions such as type 2 diabetes, cancer, and asthma.
The new prices are expected to take effect in 2027.
Between November 2023 and October 2024, these selected drugs accounted for about $41 billion in total covered prescription drug costs under Medicare Part D, or about 14%, according to the U.S. Department of Health and Human Services (HHS).
“Today’s announcement is pivotal -- the Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest of people with Medicare to have access to innovative, life-saving treatments at lower costs," Xavier Becerra, HHS secretary under the Biden administration, said in the release.
Drugs selected for this second round of negotiations include:
-
Trelegy Ellipta
-
Pomalyst
-
Ibrance
-
Ofev
-
Linzess
-
Calquence
-
Austedo; Austedo XR
-
Breo Ellipta
-
Tradjenta
-
Xifaxan
-
Janumet; Janumet XR
-
Otezla
The new talks follow last year’s negotiations for 10 high-cost drugs, which resulted in price cuts of 38% to 79%. Those discounts, effective in 2026, are projected to save Medicare $6 billion annually.
Officials plan to expand negotiations to include 15 more drugs in the next cycle and up to 20 more in following years.
“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.
Sources
- Centers for Medicare & Medicaid Services, news release, Jan. 17, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
U.S. Stops Funding for Gavi Global Vaccine Program, Sparking Backlash
FRIDAY, June 27, 2025 — The United States will stop sending money to Gavi, a global group that helps vaccinate children in low-income countries, U.S. Health and Human...
Everyday Packaging May Shed Tiny Plastics Into Your Food, Study Finds
FRIDAY, June 27, 2025 — Opening a bottle or unwrapping a piece of deli meat could be adding tiny plastic particles to your food, new research reveals. Microplastics and...
High-Fiber Diet Reduces Risk of Hardened Arteries
FRIDAY, June 27, 2025 — Noshing on veggies, grains, beans and other high-fiber foods can help your heart as well as your gut health, a new study says. People with low-fiber...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.